So far, only clinical and in vitro data were available, which showed that Fra-2 overexpression is associated with a significantly shorter disease-free survival for breast cancer patients and in Fra-2 overexpressing cell lines Fra-2 dysregulates genes involved in cell–cell and cell–matrix contacts (Schroder et al. 2010; Milde-Langosch et al. 2008). Here, FOSL2 is linked to breast carcinoma.